



## **IN8bio to Present at the TD Cowen 45th Annual Health Care Conference**

February 26, 2025

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- [IN8bio, Inc.](https://investors.in8bio.com) (**Nasdaq: INAB**), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 45<sup>th</sup> Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET.

A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at <https://investors.in8bio.com>.

### **About IN8bio**

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program INB-400 is in a Phase 2 trial in GBM. Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit [www.IN8bio.com](http://www.IN8bio.com).

### **Investor & Corporate Contact**

Glenn Schulman, PharmD, MPH  
IN8bio, Inc.  
203.494.7411  
[gdschulman@IN8bio.com](mailto:gdschulman@IN8bio.com)

### **Media Contact**

Kimberly Ha  
KKH Advisors  
917.291.5744  
[kimberly.ha@kkhadvisors.com](mailto:kimberly.ha@kkhadvisors.com)